Spartan Bioscience Announces New Clinical Study Examining Personalized Testing and Treatment for Heart Attack Patients

Share Article

200-patient clinical study is utilizing rapid CYP2C19 genotyping

Spartan RX: On-demand DNA testing

The Sinai Center for Thrombosis Research is a leader in the field of personalized antiplatelet therapy. We are honored to support their research with Spartan’s rapid CYP2C19 genotyping system.-Paul Lem, M.D., CEO of Spartan Bioscience

Spartan Bioscience today announced the start of a 200-patient clinical study of personalized medicine with the Sinai Center for Thrombosis Research at Sinai Hospital of Baltimore. The Spartan RX CYP2C19 System is being used to test heart attack patients receiving cardiac stents.

The CYP2C19*2 genetic mutation is carried by approximately 30% of Caucasians, 50% of Asians, and 55% of Indians.(1,2,3,4) Genetic carriers who receive Plavix (clopidogrel) following a cardiac stent have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(5) Over 1 million cardiac stent procedures are performed annually in the United States.(1) Following this procedure, patients are typically prescribed clopidogrel for one year or more. Plavix® is one of the best-selling drugs in the world, with over $9 billion in revenues in 2009.

“The Sinai Center for Thrombosis Research is a leader in the field of personalized antiplatelet therapy,” said Paul Lem, M.D., CEO of Spartan Bioscience. “We are honored to support their research with Spartan’s rapid CYP2C19 genotyping system.”

About CYP2C19
The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(6), including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(1,2,3,4)

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing.(7) Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.
Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

1. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
2. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
3. Oh IY et al. (2012). Heart. 98(2):139–44.
4. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.
5. Mega JL et al. (2009). N Engl J Med. 360:354–62.
6. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
7. Roberts JD et al. (2012). Lancet. 379:1705–11.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Kira Watson
Spartan Bioscience Inc.
+1 613-228-7756 Ext: 708
Email >
Visit website